Leading biotech firm Intas Biopharmaceuticals will invest Rs 160 crore to set up a new drug manufacturing facility at Sanand near Ahmedabad.
The facility, dedicated for Monoclonal Antibodies (MAbs), will undertake large-scale manufacturing of the recombinant product with a capacity of 5000L in phases.
Intas has signed a Memorandum of Understanding (MoU) with the government of Gujarat for availing special incentives for the project.
Dr. Dhananjay Patankar, Chief Technical Officer, Intas said: “The commercial production at the proposed MAbs facility is likely to commence by 2011. We have initiated the necessary technical studies for the project."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app